Söndag 22 December | 06:43:43 Europe / Stockholm

Kalender

Tid*
2025-01-16 N/A Bokslutskommuniké 2024
2024-09-13 - Kvartalsrapport 2024-Q2
2024-06-25 - X-dag ordinarie utdelning VIRP 1.32 EUR
2024-06-21 - Årsstämma
2024-06-21 - Extra Bolagsstämma
2024-03-19 - Bokslutskommuniké 2023
2023-09-15 - Kvartalsrapport 2023-Q2
2023-06-26 - X-dag ordinarie utdelning VIRP 1.32 EUR
2023-06-20 - Årsstämma
2023-06-20 - Extra Bolagsstämma
2023-01-18 - Bokslutskommuniké 2022
2022-09-15 - Kvartalsrapport 2022-Q2
2022-06-24 - X-dag ordinarie utdelning VIRP 1.25 EUR
2022-06-21 - Årsstämma
2022-06-21 - Extra Bolagsstämma
2022-03-22 - Bokslutskommuniké 2021
2021-10-18 - Kvartalsrapport 2021-Q3
2021-07-20 - Kvartalsrapport 2021-Q2
2021-06-23 - X-dag ordinarie utdelning VIRP 0.75 EUR
2021-06-21 - Årsstämma
2021-06-21 - Extra Bolagsstämma
2021-04-15 - Kvartalsrapport 2021-Q1
2021-03-22 - Bokslutskommuniké 2020
2021-01-04 - Extra Bolagsstämma
2020-12-15 - Extra Bolagsstämma
2020-10-14 - Kvartalsrapport 2020-Q3
2020-07-20 - Kvartalsrapport 2020-Q2
2020-06-22 - Årsstämma
2019-10-11 - Kvartalsrapport 2018-Q3
2019-09-16 - Kvartalsrapport 2018-Q2
2019-06-18 - Extra Bolagsstämma
2024-09-13 17:45:00
 

 
 

During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders’ meeting on June 20, 2023, decided to reduce the share capital of Virbac by canceling 67,340 treasury shares. These shares were acquired during 2023 under the share buyback program authorized by the same shareholders’ meeting.

As of today, the share capital of Virbac amounts to €10,448,325, represented by 8,390,660 shares of €1.25, fully paid-up.

Following this capital reduction, the Dick family group holds 50.09% of the share capital of Virbac and 66.20% of its voting rights.

Information on the total number of voting rights and shares, as well as the shareholder structure, will be updated on the company's website corporate.virbac.com.

 

Focusing on animal health, from the beginning
At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Press contacts - Agence Libremullenlowe

 

Anne Da Silva Passos - a.dasilvapassos@libremullenlowe.fr - +33 7 60 53 99 28